Synthetic Biologics, Inc, a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.
- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to support multiple inflection points for VCN-01...
Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that VCN Biosciences, S.L.'s (VCN) VCN-01 received Orphan Drug Designation for retinoblastoma from the US Food & Drug Administration (FDA).